doi: 10.1016/s0264-410x(97)00002-9.
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly
Affiliations
- PMID: 9269057
- DOI: 10.1016/s0264-410x(97)00002-9
Item in Clipboard
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly
Vaccine.
1997 Jul.
Free article
Abstract
The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in an open label study in 37 frail institutionalized persons over age 65. Vaccination was well tolerated without significant side-effects. Thirty-six of 37 volunteers completed the study. Nineteen of 36 (53%) vaccinees had a greater than or equal to fourfold increase in IgG to F protein at 4 weeks and 17 (47%) had a greater than or equal to fourfold rise in neutralizing titers to either group A or B virus. Although response rate to PFP-2 vaccine in the frail elderly was somewhat diminished compared to results in the healthy elderly, the vaccine was well tolerated and relatively immunogenic.
Similar articles
-
Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.Vaccine. 2019 May 6;37(20):2694-2703. doi: 10.1016/j.vaccine.2019.04.011. Epub 2019 Apr 12. Vaccine. 2019. PMID: 30987852 Clinical Trial.
-
Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.Vaccine. 1995 Aug;13(12):1095-101. doi: 10.1016/0264-410x(95)00034-x. Vaccine. 1995. PMID: 7491817 Clinical Trial.
-
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.Vaccine. 1996 Sep;14(13):1214-8. doi: 10.1016/s0264-410x(96)00030-8. Vaccine. 1996. PMID: 8961507 Clinical Trial.
-
Respiratory syncytial virus infection in older persons.Vaccine. 1998 Nov;16(18):1775-8. doi: 10.1016/s0264-410x(98)00142-x. Vaccine. 1998. PMID: 9778756 Review.
-
Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1817-1827. doi: 10.1007/s10096-018-3289-4. Epub 2018 Jun 6. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29876771 Review.
Cited by
-
Respiratory viral infections in the elderly.Antiviral Res. 1999 Dec 15;44(2):79-102. doi: 10.1016/s0166-3542(99)00062-5. Antiviral Res. 1999. PMID: 10669259 Free PMC article. Review.
-
Vaccine prevention of acute otitis media.Curr Allergy Asthma Rep. 2001 Jul;1(4):358-63. doi: 10.1007/s11882-001-0049-8. Curr Allergy Asthma Rep. 2001. PMID: 11892059 Free PMC article. Clinical Trial.
-
Respiratory syncytial virus infection in adults.Clin Microbiol Rev. 2000 Jul;13(3):371-84. doi: 10.1128/CMR.13.3.371. Clin Microbiol Rev. 2000. PMID: 10885982 Free PMC article. Review.
-
Active immunization in the United States: developments over the past decade.Clin Microbiol Rev. 2001 Oct;14(4):872-908, table of contents. doi: 10.1128/CMR.14.4.872-908.2001. Clin Microbiol Rev. 2001. PMID: 11585789 Free PMC article. Review.
-
Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.J Virol. 2001 Nov;75(22):11079-87. doi: 10.1128/JVI.75.22.11079-11087.2001. J Virol. 2001. PMID: 11602747 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
